Multicenter prospective randomized controlled trial of Vonoprazan and Esomeprazole in initial treatment for reflux esophagitis: Focusing on recurrence during maintenance therapy - VERET study

Matsumura Tomoaki0 个研究点目标入组 120 人开始时间: 2021年3月12日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•Patients who meet all of the following criteria will
•be included:
•1) Patients with reflux esophagitis: patients with erosive esophagitis of Los Angeles classification grade A-D with endoscopic examination.
•2) Patients with hearburn symptoms
•3) Age of 20 years or older (any gender).
•4) Patients who have been fully informed of and have obtained written consent of their own free will
•to participate in the study

•Applicants who meet any of the following conditions are not eligible
•1) Highly obese patients with a body mass index (BMI) of 35 or higher
•2) Patients with hiatus hernia (3cm or more)
•3) Patients taking other antacids, including PPIs (e.g. histamine H2 receptor antagonists) within 14 days prior to obtaining consent
•4) Patients who have taken regular NSAIDs, including glucocorticosteroids and COX-2 inhibitors, on at least 3 consecutive days per week within the past 28 days; exception: regular intake of up to 150 mg/day of acetylsalicylic acid.
•5) Patients with a history of esophageal, gastric or duodenal surgery.
•6) Patients with esophageal stenosis
•7) Patients with scleroderma
•8) Patients who may have an allergic reaction to the study drug
•9) Patients with substance abuse or health, psychological, or social conditions that interfere with participation in the study and the evaluation of results
•10) Pregnant women, lactating women, and patients who may or will become pregnant (a pregnancy test should be performed if pregnancy is suspected)
•11) Patients who are deemed unsuitable for inclusion by the principal investigator or sub-physician.

发起方

Matsumura Tomoaki